Skip Navigation
 
 
 
 xxx
 
Print This Page
Share this page: More
 

About Us

Public Health Statement

The goal of the Morris K. Udall Parkinson's Disease Research Center of Excellence is to understand the pathogenesis of Parkinson’s disease and related disorders in order to develop new targets and treatments for these conditions.

Our research focuses on the most common autosomal recessive (parkin) and autosomal dominant PD (LRRK2) linked genes and alpha-synuclein due to their potential role in both sporadic and familial PD. We use molecular, transgenic, neuropathologic, cell biologic and neurobehavioral approaches to investigate the roles of these genes in the symptoms and pathogenesis of PD.

Understanding the molecular mechanisms governing the involvement of these genes in the common sporadic form of PD has the greatest potential to enhance our understanding of pathogenic mechanisms in PD and yield new treatments. The Udall Center has contributed to understanding the etiology and pathogenesis of PD through recent discoveries including:

  • the identification of PARIS
  • the identification of LRRK2 phosphosubstrates
  • the generation of adult conditional knockouts of parkin creating the first accurate model of neurodegeneration in PD
  • the discovery of the enzymatic function of parkin, DJ-1 and LRRK2
  • the identification of novel targets to slow the progression of PD by targeting the molecular mechanisms by which genetic mutations cause PD.

Current research continues the search for new treatments through further elucidation of the molecular mechanisms of PD as well as the evaluation of possible clinical biomarkers of PD.

Resources Available

  • Animal models
    • Parkin knockouts (germline and conditional)
    • DJ-1 knockouts
    • Alpha-synuclein transgenics
    • LRRK2 knockouts
    • LRRK2 transgenics
    • AIMP2 transgenics
  • Human postmortem PD and related disorder brains
  • Expression constructs for most PD related genes
  • Stable cell culture models
  • Antibody production
  • Viral expression systems
  • iPSC models of PD

Publications

Recent publications in prominent journals including Nature Medicine and Cell highlight recent progress.

Johns Hopkins researchers are studying LRRK2, a protein whose mutant overactive form can lead to Parkinson's disease. Understanding the mechanism of LRRK2's activity allows researchers to search for drugs to target LRRK2. In the August 22, 2010 issue of Nature Medicine our scientists reported that certain drugs can inhibit LRRK2. A few of inhibitors of LRRK2 provided protection against nerve cell death, a symptom of Parkinson's disease.

Two of the drugs, when injected into mice showing Parkinson's disease-like changes in their brain, provided protection against nerve cell death. This makes inhibition of LRRK2 a promising target for human drug development for the treatment of Parkinson's disease. Read about it here:

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM.
Nat Med. 2010 Sep;16(9):998-1000. Epub 2010 Aug 22. PMID:20729864

Other research shows that a drug already used for human cancer treatment could lead to the development of a treatment for Parkinson's disease. In the September 21, 2010 issue of the Proceedings of the National Academy of Sciences (PNAS) our scientists report the findings that a protein called c-Abl disrupts the protein parkin, a protein that protects brain cells from being destroyed.

By disrupting parkin function, c-Abl allows for brain cell death that contributes to Parkinson's disease. Commercially available cancer treatment drugs, such as imatinib (Gleevec) target c-Abl, indicating a possibility of a brain-permeable c-Abl inhibitor as a promising treatment for Parkinson's disease. Read about it here:

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.
Ko, H.S., Lee, Y., Shin, J.H., Karuppagounder, S.S., Gadad, B.S., Koleske, A.J., Pletnikova, O., Troncoso, J.C., Dawson, V.L., and Dawson, T.M.
Proc. Natl. Acad. Sci. USA 2010 Sep; 21(107):16691'16696

A recent study published March 4, 2011 in Cell identified a key player in brain cell death as a result of parkin inactivation. PARIS, a toxic protein, accumulates when the protective protein parkin is disabled. This leads to brain cell death increasing the progression of Parkinson's disease. This makes PARIS a new target to develop treatment to slow or halt the progression of Parkinson's disease. Read about it here:

PARIS (ZNF746) Repression of PGC-1a Contributes to Neurodegeneration in Parkinson's disease.
Shin et al., Cell (2011), doi:10.1016/j.cell.2011.02.010

These studies, taken together, show the many recent advances made by our Udall Center investigators to understand the mechanisms causing Parkinson's disease and to find treatment targets to slow or halt the disease.

More Publications

Dr. Crain's Publications

Co-existence of Parkinson's disease and progressive supranuclear palsy: case report and a review of the literature.
Abhinav K, Marsh L, Crain B, Reich SG, Biglan K.
Neurol Sci. 2011 Feb;32(1):159-63. Epub 2010 Aug 25.

Age, Alzheimer's disease and dementia in the Baltimore Longitudinal Study of Ageing.
Dolan D, Troncoso J, Resnick SM, Crain BJ, Zonderman AB, O'Brien RJ.
Brain. 2010 Aug;133(Pt 8):2225-31. Epub 2010 Jul 20.

Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA).
O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, Rudow G, Iacono D, Riudavets MA, Driscoll I, Price DL, Martin LJ, Troncoso JC.
J Alzheimers Dis. 2009;18(3):665-75.

Morphometry of the human substantia nigra in ageing and Parkinson's disease.
Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC.
Acta Neuropathol. 2008 Apr;115(4):461-70. Epub 2008 Feb 23.

Drs. Dawson's publications

A lysosomal lair for two pathogenic proteins.
Dawson, T.M. and V.L. Dawson. 
Science Translational Medicine, 2011 Jul 13;3(91):91ps28 (2011) PMID: 21753118

Familial Parkinson’s disease iPSCs show cellular deficits in mitochondrial responses that can be pharmacologically rescued.
Cooper, O., H. Seo, S. Andrabi, C. Guardia-Laguarta, J. Graziotto, M. Sundberg, J.R. McLean, L. Carrillo-Reid, Z. Xie, T. Osborn, G. Hargus, M. Deleidi, T. Lawson, H. Bogetofte, E. Perez-Torres, L. Clark, C. Moskowitz, J. Mazzulli, L. Chen, L. Volpicelli-Daley, N. Romero, H. Jiang, R.J. Uitti, Z. Huang, G. Opala, L.A. Scarffe, V.L. Dawson, C. Klein, J. Feng, O.A. Ross, J.Q. Trojanowski, V.M.-Y. Lee, K. Marder, D.J. Surmeier, Z.K. Wszolek, S. Przedborski1, D. Krainc, T.M. Dawson, O. Isacson.
Science Translational Medicine 4, 141ra90 (2012); DOI: 10.1126/scitranslmed.3003985. PMCID: PMC3462009

Sulhydration mediates neuroprotective actions of Parkin.
Vandiver, M.S., B.D. Paul, R. Xu, S. Karuppagounder, F. Rao, A.M. Snowman, H.S. Ko, Y.I. Lee, V.L. Dawson, T.M. Dawson, N. Sen, S.H. Snyder.
Nature Communications, (2013) 4:1626 | DOI: 10.1038/ncomms2623 |www.nature.com/naturecommunications. PMID: 23535647, PMCID: PMC3622945

Parthanatos Mediates AIMP2 Activated Age Dependent Dopaminergic Neuronal Loss.
Lee, Y., S.S. Karuppagounder, J.-H. Shin, Y.-I. Lee. H.S. Ko, D. Swing, B.D. Lee. H.C. Kang, L. Tessarollo, V.L. Dawson and T.M. Dawson.
Nature Neuroscience, (2013). Oct;16(10):1392-400. doi: 10.1038/nn.3500. Epub 2013 Aug 25. PMID: 23974709, PMCID: PMC3785563

Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease.
Martin, I., J.W. Kim, B.D Lee, H.C. Kang, J.-C. Xu., H. Jia, J. Stankowski, M.-S. Kim, J. Zhong, M. Kumar, S. Andrabi, A Pandey, T.M. Dawson*, V.L. Dawson*. Cell. 2014 Apr 10;157(2):472-85. doi: 10.1016/j.cell.2014.01.064. PMID: 24725412 [PubMed - in process]. *Co-corresponding and senior authors.

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS.
Sci Rep. 2014 May 2;4:4874. doi: 10.1038/srep04874.PMID: 24786396. PMCID: PMC4007078

Ms. Gerstenhaber's publications

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
Laura Marsh, Kevin Biglan, Melissa Gerstenhaber, James R. Williams.
Movement Disorders 2009; 6 (2): 277'282.

Dr. Ko's Publications

Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. 
Kang HC, Lee YI, Shin JH, Andrabi SA, Chi Z, Gagné JP, Lee Y, Ko HS, Lee BD, Poirier GG, Dawson VL, Dawson TM. 
Proc. Natl. Acad. Sci. U. S. A. 2011; 108(34):14103-8. PMID: 21825151.

Sulfhydration mediates neuroprotective actions of parkin. 
Vandiver MS, Paul BD, Xu R, Karuppagounder S, Rao F, Snowman AM, Ko HS, Il Lee Y, Dawson VL, Dawson TM, Sen N, Snyder SH.
Nat Commun. 2013; 4:1626.  PMID: 23535647.

Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. 
Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D, Jiang H, Kang SU, Lee BD, Kang HC, Kim D, Tessarollo L, Dawson VL, Dawson TM.
Nat Neurosci. 2013, PMID: 23974709

The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS.
Sci Rep. 2014 May 2;4:4874. doi: 10.1038/srep04874.PMID: 24786396. PMCID: PMC4007078

Dr. Mari's Publications

Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior and thought.
Rabins, P.; Appleby, B.; Brandt, J.; DeLong, M.; Dunn, L.; Gabriëls, L.; Greenberg, B.; Haber, S.; Holtzheimer, P.; Mari, Z.; Mayberg, H.; McCann, E.; Mink, S.; Rasmussen, S.; Schlaepfer, T.; Vawter, D.; Vitek, J.; Walkup, J. and Mathews, D. Archives of General Psychiatry, 66(9): 931-7, 2009. PMID: 19736349, PMCID: PMC2753479

The Parkinson Progression Marker Initiative (PPMI).
Marek, K.; Jennings, D.; Lasch, S.; Siderowf, A.; Tanner, C.; Simuni, T.; Coffey, C.; Kieburtz, K.; Flagg, E.; Chowdhury, S.; Poewe, W.; Mollenhauer, B.; Sherer, T.; Frasier, M.; Meunier, C.; Rudolph, A.; Casaceli, C.; Seibyl, J.; Mendick, S.; Schuff, N.; Zhang, Y.; Toga, A.; Crawford, K.; Ansbach, A.; De Blasio, P.; Piovella, M.; Trojanowski, J.; Shaw, L.; Singleton, A.; Hawkins, K.; Eberling, J.; Brooks, D.; Russell, D.; Leary, L.; Factor, S.; Sommerfeld, B.; Hogarth, P.; Pighetti, E.; Williams, K.; Standaert, D.; Guthrie, S.; Hauser, R.; Delgado, H.; Jankovic, J.; Hunter, C.; Stern, M.; Tran, B.; Leverenz, J.; Baca, M.; Frank, S.; Thomas, C.A.; Richard, I.; Deeley, C.; Rees, L.; Sprenger, F.; Lang, E.; Shill, H.; Obradov, S.; Fernandez, H.; Winters, A.; Berg, D.; Gauss, K.; Galasko, D.; Fontaine, D.; Mari, Z.; Gerstenhaber, M.; Brooks, D.; Malloy, S.; Barone, P.; Longo, K.; Comery, T.; Ravina, B.; Grachev, I.; Gallagher, K.; Collins, M.; Widnell, KL.; Ostrowizki, S.; Fontoura, P.; La-Roche, F.H.; Ho, T.; Luthman, J.; van der Brug, M.; Reith, A.D. and Taylor, P.
Prog Neurobiol, 95(4): 629-35, 2011 (ROLE: coauthor, site PI). PMID: 21930184

Design innovations and baseline findings in a long-term Parkinson's trial: The national institute of neurological disorders and stroke exploratory trials in Parkinson's Disease Long-Term Study-1.
Elm, J. and The NINDS NET-PD Investigators.
Movement Disorders, 27 (12): 1513-1521, 2012 (ROLE: coauthor, site PI). PMID: 23079770, PMCID: PMC3481179

Dopamine Transporter Imaging in Psychogenic Parkinsonism and Neurodegenerative Parkinsonism with Psychogenic Overlay: A Report of Three Cases.
Umeh, C.C.; Szabo, Z.; Pontone, G.M. and Mari, Z.
Tremor Other Hyperkinet Mov (NY). 2013 Sep 10;3. doi:pii: tre-03-188-4324-2. PMID: 24137554, PMCID: PMC3777435.

Mobility, mood and site of care impact health related quality of life in Parkinson's disease.
Nutt J, Siderowf A, Guttman M, Schmidt P, Zamudio J, Wu S, Okun M, Simuni T, Parashos S, Dahodwala N, Davis T, Giladi N, Gurevich T, Hauser R, Jankovic J, Lyons K, Marsh L, Miyasaki J, Morgan J, Santiago A, Tarsy D, Mari Z, Malaty I, Nelson E; The National Parkinson Foundation Quality Improvement Initiative Investigators.
Parkinsonism Relat Disord. 2014 Mar;20(3):274-9. doi: 10.1016/j.parkreldis.2013.10.004. Epub 2013 Oct 16. PMID: 24182524.

Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner CM, Singleton A, Toga AW, Chowdhury S, Mollenhauer B, Trojanowski JQ, Shaw LM; Parkinson's Progression Markers Initiative.
JAMA Neurol. 2013 Oct;70(10):1277-87. PMID: 23979011, PMCID: PMC4034348.

Falls in Parkinson disease: analysis of a large cross-sectional cohort.
Parashos SA, Wielinski CL, Giladi N, Gurevich T; National Parkinson Foundation Quality Improvement Initiative Investigators.
J Parkinsons Dis. 2013;3(4):515-22. doi: 10.3233/JPD-130249. PMID: 24113557.

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of Benefit.
Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.
JAMA Neurol. 2014 Mar 24. doi: 10.1001/jamaneurol.2014.131. [Epub ahead of print] PMID: 24664227

Timed up and go, cognitive, and quality-of-life correlates in Parkinson's disease.
Stegemöller EL, Nocera J, Malaty I, Shelley M, Okun MS, Hass CJ; NPF Quality Improvement Initiative Investigators.
Arch Phys Med Rehabil. 2014 Apr;95(4):649-55. doi: 10.1016/j.apmr.2013.10.031. Epub 2013 Nov 27. PMID: 24291596.

The past, present, and future of telemedicine for Parkinson's disease.
Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, Ray Dorsey E, Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson JR; on behalf of the International Parkinson and Movement Disorder Society Telemedicine Task Force.
Mov Disord. 2014 May 17. doi: 10.1002/mds.25903. [Epub ahead of print]. PMID: 24838316.

REM sleep behavior and motor findings in Parkinson’s disease: a cross sectional analysis.
Mahajan A, Gamaldo C, Salas RM, Pontone G, Umeh C, Rosenthal L, McCoy A, Mari Z.
Tremor Other Hyperkinet Mov. 2014 (IN PRESS)

Clinical Trials in Neurology 2013: Movement Disorders.
Dorsey, E.R. and Mari, Z. JAMA Neurology 2014 (ACCEPTED).


Dr. Pandey’s Publications

Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson’s disease.
Martin, I., J.W. Kim, B.D Lee, H.C. Kang, J.-C. Xu., H. Jia, J. Stankowski, M.-S. Kim, J. Zhong, M. Kumar, S. Andrabi, A Pandey, T.M. Dawson*, V.L. Dawson*.
Cell. 2014 Apr 10;157(2):472-85. doi: 10.1016/j.cell.2014.01.064. PMID: 24725412 [PubMed - in process]. *Co-corresponding and senior authors. 


Dr. Pletnikova's publications

Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, Jenkins NA, Copeland NG, Galter D, Thomas B, Lee MK, Dawson TM, Dawson VL, Moore DJ.
PLoS One. 2011 Apr 6;6(4):e18568.

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM.
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. Epub 2010 Sep 7.

S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease
Tsang AH, Lee YI, Ko HS, Savitt JM, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Chung KK.
Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4900-5. Epub 2009 Mar 9. Erratum in: Proc Natl Acad Sci U S A. 2009 May 26;106(21):8791.

Morphometry of the human substantia nigra in ageing and Parkinson's disease
Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC.
Acta Neuropathol. 2008 Apr;115(4):461-70. Epub 2008 Feb 23.

Dr. Pontone's publications

Which Scale to Use? A Comparison of Nine Scales to Detect Depression in Parkinson’s Disease. 
Williams JR, Hirsch ES, Anderson K, Bush AL, Goldstein SR, Grill S, Lehmann S, Little JT, Margolis RL, Pontone GM, Weiss H, Rabins PV, Marsh L.
Neurology. 2011 Mar 27;78(13):998-1006. PMCID: PMC3310315

Dr. Troncoso's Publications

Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases.Tan JMM, Wong ESP, Kirkpatrick D, Pletnikova O, Ko JS, Tay S, Ho MWL, Troncoso JC, Gygi SP, Lee MK, Dawson VL, Dawson TM, Lim K.
Hum Mol Genet. 1;17(3):431-9, 2008. 

Morphometry of the human substantia nigra in ageing and Parkinson's disease. 
Rudow GL, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso, JC.
Acta Neuropathol. 2008. 115(4):461-70, 2008. PMID: 18297291. PMCID: PMC2431149

S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. 
Tsang AH, Lee YI, Ko HS, Savitt JM, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM, Chung KK.
Proc Natl Acad Sci U S A. 106(12):4900–4905, 2009. PMID: 19273858. PMCID: PMC2660786

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.
Höglinger GU et al.
Nat Genet. 2011;19;43(7):699-705. doi: 10.1038/ng.859. PMCID: PMC3125476.

Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum occurs in alpha-synucleinopathy in vivo. 
Colla E, Jensen P, Pletnikova O, Troncoso JC, Glabe C, Lee M. J
Neurosci. 2012;7; 32(10):3301-5. PMCID: PMC3461828

PARK9-Associated ATP13A2 Localizes to Intracellular Acidic Vesicles and Regulates Cation Homeostasis and Neuronal Integrity.
Ramonet D, Podhajska A, Stafa K, Sonnay S, Trancikova A, Tsika E, Pletnikova O, Troncoso JC, Glauser L, Moore DJ. 
Hum Mol Genet. 2012;15;21(8):1725-43. PMCID: PMC3465694

PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. 
Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troncoso JC, Dawson VL, Dawson TM.
Cell. 2011;144(5):689-702. PMCID: PMC3063894, NIHMS272251.

Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. 
Daher JP, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D, Troncoso JC, Lee MK, Dawson TM, Dawson VL, Moore DJ.
Hum Mol Genet. 2012;21(11):2420-31. PMCID: PMC3349422.

Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. 
Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, Schneider BL, Lee MK.  
J Neurosci. 2012; 32(10):3306-20.  PMCID: PMC3461828, NIHMS362341.

MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ, Liu G, Jin SM, Parisiadou L, Xie C, Yu J, Sun L, Ma B, Ding J, Vancraenenbroeck R, Lobbestael E, Baekelandt V, Taymans JM, He P, Troncoso JC, Shen Y, Cai H. 
Hum Mol Genet. 2012;1;22(3):608-20. doi: 10.1093/hmg/dds470. PMCID: PMC3542867

Aldehyde dehydrogenase 1 determines the regional selectivity of nigral neuron loss in Parkinson disease. 
Liu G, Ding J, Xie C, Sun L, Rudow G, Troncoso JC, Cai H.  
J Clin Invest. 2014 May 27. pii: 72176. doi: 10.1172/JCI72176. [Epub ahead of print PMID: 24865427

 
 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer